Respironics Awakens In April; Strong Sales Spark 13% Stock Price Gain
This article was originally published in The Gray Sheet
Executive Summary
Respironics' third-quarter results awakened Wall Street to the fact that the sleep-disorder equipment manufacturer had shrugged off its recent reimbursement difficulties. The company's stock price was up 13%, or 1-7/8, in April, closing the month at 16-1/4.
You may also be interested in...
Respironics Investors Breathing Easy After Turnaround; Stock Up 25% In Nov.
An accelerating growth rate and positive news highlighted at Respironics' Nov. 16 annual shareholder meeting breathed new life into the company's stock price. The issue closed Nov. 30 at $24.56, up $4.93, or 25.1%, for the month.
Respironics Investors Breathing Easy After Turnaround; Stock Up 25% In Nov.
An accelerating growth rate and positive news highlighted at Respironics' Nov. 16 annual shareholder meeting breathed new life into the company's stock price. The issue closed Nov. 30 at $24.56, up $4.93, or 25.1%, for the month.
Itamar Pursuing Sleep Apnea As First Application Of PAT Platform
Respironics will distribute Itamar Medical's peripheral arterial tonometry technology (PAT) with its sleep monitoring instruments to assist in the diagnosis of sleep apnea.